|
3 |
Clinical Trial entitled “A Randomized, Open-label, Assessor Blind, Parallel, Active Controlled, Multicentric, Bridging Clinical Trial To Evaluate the Immunogenicity And Safety of Three Dose Thrabis Vaccine (Recombinant Rabies G Protein Vaccine), Administered as a Simulated Post-exposure Immunization in Healthy Children. From April 2023 as Lead investigator.
|
Funded |
Cadila pharma |
|